Psilocybin
Filament Health, NeoLumina Partner to Trial Psilocybin Drug for Eating Disorders
Filament is set to receive up to "seven figures" in milestone payments.
The post Filament Health, NeoLumina Partner to Trial Psilocybin Drug for Eating…
Clinical-stage psychedelic drug developer Filament Health Corp. (OTCQB: FLHLF) is teaming up with NeoLumina Bioscience Inc. to help test a psilocybin-based drug for eating disorders, the company said Friday.
The licensing agreement allows NeoLumina to use Filament’s proprietary botanical psilocybin drug candidate, PEX010, for its clinical and commercial development to address eating disorders.
PEX010, which is orally administered, received authorization from both the U.S. Food and Drug Administration and Health Canada to commence phase 1 and phase 2 human clinical trials.
“Nearly 10% of the global population suffers from an eating disorder and there are no approved drugs for most types,” NeoLumina CEO Gaetano Morello said in a statement.
NeoLumina is a life sciences company looking to develop “better first-line therapeutic candidates for mental health conditions that are based on psychedelic molecules,” the company said. The licensing agreement provides NeoLumina exclusive use of PEX010 for eating disorders. Additionally, the agreement stipulates that Filament will supply PEX010 to NeoLumina for research.
Under the terms of the contract, Filament is set to receive up to “seven figures” in milestone payments during NeoLumina’s clinical development phase and marketing authorization process. Future commercial royalties up to a low double-digit percentage of net sales are also included in the deal.
NeoLumina joins an expanding roster of Filament’s licensing partners, all utilizing PEX010 to further their clinical trial programs. Current partners are engaged in studies for conditions including opioid tapering, palliative care and alcohol use disorder.
The post Filament Health, NeoLumina Partner to Trial Psilocybin Drug for Eating Disorders appeared first on Green Market Report.
psilocybin psychedelic deal filament health filament authorization health canada research
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin6 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation5 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research